113 related articles for article (PubMed ID: 20347318)
21. Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I).
Li X; Wang J; Li J; Wu J; Li Y; Zhu H; Fan R; Xu W
Bioorg Med Chem; 2009 Apr; 17(8):3053-60. PubMed ID: 19329328
[TBL] [Abstract][Full Text] [Related]
22. Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells.
Cui SX; Qu XJ; Gao ZH; Zhang YS; Zhang XF; Zhao CR; Xu WF; Li QB; Han JX
Cancer Lett; 2010 Jun; 292(2):153-62. PubMed ID: 20042271
[TBL] [Abstract][Full Text] [Related]
23. Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part II).
Li X; Wang Y; Wu J; Li Y; Wang Q; Xu W
Bioorg Med Chem; 2009 Apr; 17(8):3061-71. PubMed ID: 19339187
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and activity evaluation of a new bestatin derivative LYP2 as an aminopeptidase N inhibitor.
Luan Y; Wang Q; Liu N; Mou J; Jiao X; Fang H; Li M; Xu W
Anticancer Drugs; 2011 Jan; 22(1):99-103. PubMed ID: 21048494
[TBL] [Abstract][Full Text] [Related]
25. Novel leucine ureido derivatives as inhibitors of aminopeptidase N (APN).
Ma C; Jin K; Cao J; Zhang L; Li X; Xu W
Bioorg Med Chem; 2013 Apr; 21(7):1621-7. PubMed ID: 23453219
[TBL] [Abstract][Full Text] [Related]
26. Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.
Jia M; Yang K; Fang H; Xu Y; Sun S; Su L; Xu W
Bioorg Med Chem; 2011 Sep; 19(17):5190-8. PubMed ID: 21802307
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13.
Liu Y; Shang L; Fang H; Zhu H; Mu J; Wang Q; Wang X; Yuan Y; Xu W
Bioorg Med Chem; 2009 Oct; 17(20):7398-404. PubMed ID: 19782572
[TBL] [Abstract][Full Text] [Related]
29. Global and focused transcriptional profiling of small molecule aminopeptidase N inhibitor reveals its mechanism of angiogenesis inhibition.
Shim JS; Park HM; Lee J; Kwon HJ
Biochem Biophys Res Commun; 2008 Jun; 371(1):99-103. PubMed ID: 18413233
[TBL] [Abstract][Full Text] [Related]
30. Selective aminopeptidase-N (CD13) inhibitors with relevance to cancer chemotherapy.
Schmitt C; Voegelin M; Marin A; Schmitt M; Schegg F; Hénon P; Guenot D; Tarnus C
Bioorg Med Chem; 2013 Apr; 21(7):2135-44. PubMed ID: 23428964
[TBL] [Abstract][Full Text] [Related]
31. The synthesis and preliminary activity assay in vitro of peptide-like derivatives as APN inhibitors.
Li SH; Li G; Huang HM; Xiong F; Liu CM; Tu GG
Arch Pharm Res; 2008 Oct; 31(10):1231-9. PubMed ID: 18958412
[TBL] [Abstract][Full Text] [Related]
32. Exploring S1 plasticity and probing S1' subsite of mammalian aminopeptidase N/CD13 with highly potent and selective aminobenzosuberone inhibitors.
Revelant G; Al-Lakkis-Wehbe M; Schmitt M; Alavi S; Schmitt C; Roux L; Al-Masri M; Schifano-Faux N; Maiereanu C; Tarnus C; Albrecht S
Bioorg Med Chem; 2015 Jul; 23(13):3192-207. PubMed ID: 25982416
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of 5-(4'-carboxyphenyl)-10,15,20-tris-(4 pyridyl)-porphyrin and its peptidyl phosphonate derivatives.
Habdas J; Boduszek B
J Pept Sci; 2009 Apr; 15(4):305-11. PubMed ID: 19189318
[TBL] [Abstract][Full Text] [Related]
34. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. II.
Li Q; Fang H; Wang X; Xu W
Eur J Med Chem; 2010 Apr; 45(4):1618-26. PubMed ID: 20129718
[TBL] [Abstract][Full Text] [Related]
35. A structural insight into the P1S1 binding mode of diaminoethylphosphonic and phosphinic acids, selective inhibitors of alanine aminopeptidases.
Węglarz-Tomczak E; Berlicki Ł; Pawełczak M; Nocek B; Joachimiak A; Mucha A
Eur J Med Chem; 2016 Jul; 117():187-96. PubMed ID: 27100031
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
[TBL] [Abstract][Full Text] [Related]
37. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I.
Li Q; Fang H; Wang X; Hu L; Xu W
Eur J Med Chem; 2009 Dec; 44(12):4819-25. PubMed ID: 19683842
[TBL] [Abstract][Full Text] [Related]
38. Novel β-dicarbonyl derivatives as inhibitors of aminopeptidase N (APN).
Ma C; Li X; Liang X; Jin K; Cao J; Xu W
Bioorg Med Chem Lett; 2013 Sep; 23(17):4948-52. PubMed ID: 23860593
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.
Su L; Jia Y; Wang X; Zhang L; Fang H; Xu W
Bioorg Med Chem Lett; 2013 May; 23(9):2512-7. PubMed ID: 23528299
[TBL] [Abstract][Full Text] [Related]
40. Phosphinate, sulfonate, and sulfonamidate dipeptides as potential inhibitors of Escherichia coli aminopeptidase N.
Yang KW; Golich FC; Sigdel TK; Crowder MW
Bioorg Med Chem Lett; 2005 Dec; 15(23):5150-3. PubMed ID: 16168644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
